Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Aethlon Medical, Inc. (AEMD) reported its financial results for the fiscal year ending March 31, 2020. The company generated government contract revenue of $650,187, up from $229,625 in the prior year. Operating expenses rose by 6% to approximately $6.58 million. The net loss increased to around $6.38 million, compared to $6.22 million in the previous year. Aethlon continues developing its Hemopurifier device, aiming to initiate clinical trials for advanced cancers and recently received FDA approval to treat COVID-19 patients. As of March 31, 2020, the company had a cash balance of about $9.6 million.
Aethlon Medical, Inc. (AEMD) presented encouraging data on its Hemopurifier at the AACR Virtual Annual Meeting II on June 22, 2020. The data demonstrated that the Hemopurifier effectively captures and removes tumor-derived exosomes from fluid samples of cancer patients, including those with head and neck, melanoma, ovarian, esophageal, and breast cancers. CEO Timothy C. Rodell emphasized that targeting these exosomes could enhance cancer treatment outcomes. The Hemopurifier is recognized as an FDA-designated "Breakthrough Device" for advanced cancer and critical viral infections.
Aethlon Medical (Nasdaq: AEMD) announced FDA approval for a supplement to its Investigational Device Exemption (IDE) enabling the Hemopurifier® to be tested in COVID-19 patients. The feasibility study will include up to 40 subjects in ICUs with acute lung injury and severe symptoms. The Hemopurifier, previously tested for hepatitis C and Ebola, is designated as a Breakthrough Device for life-threatening viral infections and advanced cancer. CEO Timothy C. Rodell believes the device could improve outcomes for severely affected COVID-19 patients.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced it will release its financial results for Q4 FY2020 on June 25, 2020, at 4:15 PM Eastern Time. A conference call is scheduled for the same day at 4:30 PM Eastern, where management will review results and corporate developments, followed by a Q&A session. The Hemopurifier®, Aethlon's immunotherapeutic device, has received FDA's Breakthrough Device designations for cancer and viral infections, aiming to address critical unmet needs in global health.